---
id: intravascular-device-infections_082
category: clinical_syndromes
tags: [CLABSI, CRBSI, CIED-infection, pacemaker-infection, ICD-infection, device-removal, catheter-related-infection]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Intravascular Device Infections

**Q:** What are the types, microbiology, diagnostic criteria, and management strategies for intravascular device infections (CLABSI, CRBSI, CIED infections)?

**A:**

## OVERVIEW

**Types of Intravascular Devices:**
- **Central venous catheters (CVCs):** PICC, tunneled (Hickman, Broviac, HD catheters), non-tunneled, ports
- **Cardiac implantable electronic devices (CIEDs):** Pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices
- **Peripheral IV catheters** (lower infection risk, not covered here)

---

## 1. CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI)

---

### **Definitions:**

**Central Line-Associated Bloodstream Infection (CLABSI):**
- **CDC Surveillance Definition (NHSN):**
  - **Bloodstream infection** (recognized pathogen OR common commensal from ≥2 blood cultures)
  - **Central line in place** for >2 calendar days on the date of event
  - **No other source** of infection

**Central Line-Related Bloodstream Infection (CRBSI):**
- **Clinical Definition:**
  - **Bloodstream infection** with **same organism** isolated from:
    - **Central line tip culture** (≥15 CFU by semi-quantitative method OR ≥100 CFU by quantitative)
    - **AND blood culture**
  - **OR Differential time to positivity (DTP) ≥2 hours** (central blood culture positive ≥2h before peripheral)

**Key Difference:**
- **CLABSI = surveillance definition** (epidemiology, quality metrics)
- **CRBSI = clinical diagnosis** (confirms catheter as source)

---

### **Epidemiology:**

**Incidence:**
- **250,000 CLABSIs/year in US hospitals**
- **12-25% mortality** (higher if S. aureus, Candida)
- **$45,000 additional cost per case**

**Risk Factors:**
- **Type of catheter:** Non-tunneled > PICC > tunneled > port
- **Insertion site:** Femoral > internal jugular > subclavian
- **Duration:** ↑ risk with prolonged dwell time
- **Patient factors:** Immunosuppression, critical illness, TPN, multiple lumens

---

### **Microbiology:**

| **Organism** | **Frequency** | **Key Features** |
|--------------|---------------|------------------|
| **Coagulase-Negative Staphylococci (CoNS)** | **30-40%** | *S. epidermidis* most common<br>**Biofilm producer**<br>**Contaminant vs. pathogen** (≥2 cultures needed) |
| ***Staphylococcus aureus*** | **20-25%** | **High mortality** (10-30%)<br>**Metastatic complications** (25-40%): endocarditis, osteomyelitis, epidural abscess |
| **Enterococcus** | **10-15%** | *E. faecalis*, *E. faecium* (VRE) |
| **Gram-Negative Bacilli** | **15-20%** | *E. coli*, *Klebsiella*, *Pseudomonas*, *Enterobacter* |
| ***Candida* species** | **5-10%** | *C. albicans*, *C. parapsilosis*, *C. glabrata*<br>**High mortality** (30-40%) |

**Key Point:** **CoNS = #1 CLABSI pathogen** (30-40%)

---

### **Diagnosis:**

**Criteria for CLABSI/CRBSI:**

**1. Blood Cultures:**
- **≥2 sets** (one from central line, one from peripheral)
- **Same organism** from both cultures
- **Differential time to positivity (DTP):** Central culture positive ≥2 hours before peripheral = catheter source (90% sensitivity/specificity)

**2. Catheter Tip Culture (If Line Removed):**
- **Semi-quantitative (roll-plate) method:** ≥15 CFU = positive
- **Quantitative (sonication) method:** ≥100 CFU = positive

**Key Point:** **DTP ≥2 hours = catheter source** (without removing line)

---

### **Management:**

---

#### **Step 1: Remove or Retain Catheter?**

**ALWAYS Remove:**
- **Severe sepsis / septic shock**
- ***S. aureus*, *Candida*, or *Pseudomonas* bacteremia**
- **Tunnel/port pocket infection** (erythema, purulence)
- **Persistent bacteremia** >72h despite antibiotics
- **Endocarditis or other metastatic infection**
- **Non-tunneled CVC** (easily replaced)

**Consider Retaining (With Antibiotic Lock Therapy):**
- **Tunneled catheter or port** (difficult to replace)
- **Coagulase-negative Staphylococci** (CoNS) or **Enterococcus** (NOT S. aureus, Candida, Pseudomonas)
- **No complications** (no severe sepsis, metastatic infection)
- **Clinically stable**

**Key Point:** **ALWAYS remove if S. aureus, Candida, or Pseudomonas** (high risk of complications)

---

#### **Step 2: Antibiotic Therapy**

---

**Empiric Therapy (Before Culture Results):**

| **Setting** | **Regimen** |
|-------------|-------------|
| **Non-severe, community-acquired** | **Vancomycin** 15 mg/kg IV q12h |
| **Severe sepsis / healthcare-associated / neutropenic** | **Vancomycin** 15 mg/kg IV q12h<br>**PLUS**<br>**Cefepime** 2g IV q8h OR **Piperacillin-tazobactam** 4.5g IV q6h |

**Rationale:**
- **Vancomycin:** MRSA, CoNS
- **Cefepime/pip-tazo:** Gram-negatives (including *Pseudomonas*)

---

**Directed Therapy (After Organism Identified):**

| **Organism** | **Regimen** | **Duration** |
|--------------|-------------|--------------|
| **CoNS** | **Vancomycin** 15 mg/kg IV q12h (if MRSE)<br>OR **Nafcillin** 2g IV q4h (if MSSE) | **5-7 days** (if catheter removed)<br>**10-14 days** (if catheter retained) |
| ***S. aureus*** (MSSA) | **Nafcillin** OR **Oxacillin** 2g IV q4h<br>OR **Cefazolin** 2g IV q8h | **14 days** (uncomplicated, catheter removed, TEE negative)<br>**4-6 weeks** (if TEE positive, or cannot exclude endocarditis) |
| ***S. aureus*** (MRSA) | **Vancomycin** 15-20 mg/kg IV q8-12h (trough 15-20)<br>OR **Daptomycin** 8-10 mg/kg IV q24h | **14 days** (uncomplicated)<br>**4-6 weeks** (if endocarditis) |
| **Enterococcus** | **Ampicillin** 2g IV q4h (if susceptible)<br>OR **Vancomycin** 15 mg/kg IV q12h (if VRE) | **7-14 days** |
| **Gram-Negative Bacilli** | Organism-specific (ceftriaxone, cefepime, meropenem) | **7-14 days** |
| ***Candida* species** | **Echinocandin** (caspofungin, micafungin, anidulafungin)<br>OR **Fluconazole** (if susceptible) | **14 days** after first negative blood culture (minimum 14 days) |

---

**Key Points:**
- ***S. aureus* bacteremia:** ALWAYS remove catheter + check **TEE** (rule out endocarditis)
- **Uncomplicated S. aureus CLABSI:** 14 days (if TEE negative, no metastatic foci)
- **Complicated S. aureus CLABSI:** 4-6 weeks (if endocarditis, osteomyelitis, or cannot exclude complications)
- ***Candida* CLABSI:** Remove catheter + echinocandin (first-line) OR fluconazole (if susceptible)

---

#### **Step 3: Workup for Complications (S. aureus, Candida)**

**Mandatory for *S. aureus* or *Candida* CLABSI:**
- **Repeat blood cultures** daily until clearance documented
- **Transesophageal echocardiography (TEE)** - rule out endocarditis (25-40% with S. aureus)
- **Ophthalmologic exam** (Candida - endophthalmitis)
- **If persistent fever/bacteremia:** Consider MRI spine (epidural abscess), bone scan (osteomyelitis)

---

#### **Antibiotic Lock Therapy (ALT) - Optional for Retained Catheters**

**Indication:**
- **Tunneled catheter or port** (if retained)
- **CoNS or Enterococcus** (NOT S. aureus, Candida, Pseudomonas)
- **Adjunct to systemic antibiotics**

**Regimen:**
- **Vancomycin 2-5 mg/mL** OR **Gentamicin 1-2 mg/mL** in catheter lumen (dwell ≥12 hours)
- **Duration:** 10-14 days

**Efficacy:**
- **Salvage rate 60-80%** (vs 20-30% without ALT)

**Key Point:** **ALT = adjunct only** (NOT monotherapy)

---

## 2. CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED) INFECTIONS

---

### **Types of CIED:**
- **Pacemakers**
- **Implantable cardioverter-defibrillators (ICDs)**
- **Cardiac resynchronization therapy (CRT) devices**

---

### **Epidemiology:**

**Incidence:**
- **1-2% of CIED implantations**
- **Increasing incidence** (due to ↑ device complexity, ↑ comorbidities)
- **High mortality if not treated:** 10-30%

**Risk Factors:**
- **Procedure-related:** Reoperation (replacement, revision), hematoma, prolonged procedure time
- **Patient factors:** Diabetes, renal failure, immunosuppression, anticoagulation
- **Device factors:** Lead revision, multiple leads

---

### **Types of CIED Infection:**

| **Type** | **Location** | **Features** |
|----------|--------------|--------------|
| **Pocket infection** | **Generator pocket** (subcutaneous) | **Erythema, warmth, purulence** at pocket site<br>**NO lead involvement** (localized) |
| **Lead infection** | **Intravascular leads** | **Bacteremia, vegetations on leads** (TEE)<br>**May have endocarditis** |
| **Endocarditis** | **Valve + lead vegetations** | **Bacteremia, emboli**<br>TEE: Vegetations on valve or lead |

**Key Point:** **Pocket infection alone = localized**, **Lead infection = systemic bacteremia**

---

### **Microbiology:**

| **Organism** | **Frequency** | **Key Features** |
|--------------|---------------|------------------|
| **Coagulase-Negative Staphylococci (CoNS)** | **50-60%** | *S. epidermidis* most common<br>**Early infection** (<1 year post-op)<br>**Biofilm producer** |
| ***Staphylococcus aureus*** | **20-30%** | **More acute presentation**<br>**Higher mortality** (10-30%) |
| **Gram-Negative Bacilli** | **5-10%** | *Pseudomonas*, *E. coli* |
| ***Candida* species** | **<5%** | Rare but high mortality |

**Key Point:** **CoNS = #1 CIED infection pathogen** (50-60%)

---

### **Diagnosis:**

**Clinical Presentation:**

**Pocket Infection:**
- **Erythema, warmth, swelling** at generator pocket
- **Purulent drainage**
- **Wound dehiscence**
- **Device erosion** through skin

**Lead Infection / Endocarditis:**
- **Fever, chills**
- **Positive blood cultures**
- **Embolic phenomena** (pulmonary emboli if right-sided)

---

**Diagnostic Workup:**

**1. Blood Cultures:**
- **≥2 sets** (before antibiotics)

**2. Transesophageal Echocardiography (TEE):**
- **Mandatory** if bacteremia or suspected lead infection
- **Findings:** Vegetations on leads, valves; lead perforation

**3. Imaging:**
- **Chest X-ray:** Lead position, complications
- **CT chest:** If TEE negative but high suspicion (abscess)
- **PET/CT:** Helpful if diagnosis unclear (uptake at device/leads)

---

### **Management:**

---

#### **Key Principle: COMPLETE DEVICE REMOVAL (Generator + All Leads)**

**Indication for Complete Device Removal:**
- **ANY evidence of infection:**
  - **Pocket infection** (erythema, purulence, dehiscence)
  - **Bacteremia** (especially S. aureus, CoNS, Candida)
  - **Lead vegetation** on TEE
  - **Endocarditis**
  - **Device erosion** through skin

**Key Point:** **Partial removal (generator only) = INADEQUATE** (leads must be removed)

---

#### **Device Removal Methods:**

**1. Percutaneous Lead Extraction:**
- **Preferred method** (transvenous)
- **Laser or mechanical sheaths** (to break up fibrosis/biofilm)
- **Success rate: 95-97%**
- **Complications:** Cardiac perforation (1-2%), hemothorax, tamponade, death (0.5-1%)

**2. Open Surgical Extraction:**
- If percutaneous extraction fails
- If large vegetation (>2 cm) at risk of embolization
- Requires cardiothoracic surgery

---

#### **Antibiotic Therapy:**

**Empiric (Before Culture Results):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | Until organism identified |
| **PLUS (if Gram-negatives suspected)** | | |
| **Cefepime** OR **Piperacillin-tazobactam** | 2g IV q8h OR 4.5g IV q6h | Until organism identified |

---

**Directed Therapy (After Organism Identified):**

| **Organism** | **Regimen** | **Duration After Device Removal** |
|--------------|-------------|-----------------------------------|
| **CoNS** | **Vancomycin** (if MRSE) OR **Nafcillin** (if MSSE) | **10-14 days** (pocket infection)<br>**4-6 weeks** (bacteremia/lead infection) |
| ***S. aureus*** (MSSA) | **Nafcillin** OR **Cefazolin** | **14 days** (pocket infection, TEE negative)<br>**4-6 weeks** (bacteremia or endocarditis) |
| ***S. aureus*** (MRSA) | **Vancomycin** OR **Daptomycin** | **14 days** (pocket infection)<br>**4-6 weeks** (bacteremia or endocarditis) |
| **Gram-Negative Bacilli** | Organism-specific (ceftriaxone, cefepime, etc.) | **10-14 days** |
| ***Candida*** | **Echinocandin** OR **Fluconazole** | **≥4 weeks** after device removal |

**Key Point:** **Duration starts AFTER complete device removal** (not before)

---

#### **Device Reimplantation:**

**Timing:**
- **Wait until infection cleared** before reimplantation
- **CoNS:** Reimplant after **72h negative blood cultures** (minimum 10-14 days antibiotics)
- ***S. aureus*:** Reimplant after **14 days** (if uncomplicated) OR **4-6 weeks** (if endocarditis)
- ***Candida*:** Reimplant after **≥4 weeks**

**Method:**
- **Contralateral side** (avoid infected site)
- **Alternative:** Epicardial leads (if transvenous contraindicated)

---

### **Outcomes:**

**Mortality:**
- **10-30%** if not treated (or if delayed treatment)
- **2-5%** with appropriate device removal + antibiotics

**Predictors of Poor Outcome:**
- ***S. aureus* or *Candida* infection**
- **Delayed device removal**
- **Endocarditis**
- **Renal failure, heart failure**

---

## PREVENTION

---

### **CLABSI Prevention:**

**Insertion Bundle:**
- **Hand hygiene**
- **Maximal barrier precautions** (sterile gown, gloves, drape, mask)
- **Chlorhexidine skin prep** (preferred over povidone-iodine)
- **Subclavian site** preferred (vs femoral or IJ)
- **Ultrasound guidance**

**Maintenance Bundle:**
- **Daily assessment of need** (remove if not needed)
- **Chlorhexidine-impregnated dressing**
- **Disinfect hubs** before accessing
- **Hand hygiene**

---

### **CIED Infection Prevention:**

**Perioperative Antibiotics:**
- **Cefazolin** 1-2g IV within **1 hour before incision**
- Redose if procedure >4 hours

**Antibiotic-Eluting Envelope (Tyvalzi):**
- **FDA-approved 2019**
- **Minocycline + rifampin-impregnated envelope** wrapped around device
- **Reduces CIED infection by 40%** in high-risk patients

**Other Measures:**
- **Meticulous hemostasis** (avoid hematoma)
- **Minimize procedure time**

---

**Mnemonic: "CLABSI = CoNS, Line out, Antibiotics 14d, S. aureus TEE"**
- **C**oNS = #1 pathogen (30-40%)
- **L**ine out (remove catheter if S. aureus, Candida, Pseudomonas)
- **A**ntibiotics 14 days (S. aureus, uncomplicated)
- **S**. aureus → TEE mandatory
- **I**nfection prevention (insertion/maintenance bundles)

**Mnemonic: "CIED = Complete Device Out (Generator + Leads)"**
- **C**omplete device removal (generator + all leads)
- **I**nfection = indication for removal
- **E**ndocarditis workup (TEE mandatory)
- **D**uration: 4-6 weeks (if bacteremia/endocarditis)

**Clinical Pearls:**
- **CLABSI vs CRBSI:** CLABSI = surveillance definition, CRBSI = clinical diagnosis
- **DTP ≥2 hours** (central culture positive ≥2h before peripheral) = catheter source
- **ALWAYS remove catheter if S. aureus, Candida, or Pseudomonas** CLABSI
- **S. aureus CLABSI:** ALWAYS check TEE (25-40% have endocarditis)
- **Uncomplicated S. aureus CLABSI:** 14 days (if TEE negative, catheter removed)
- **Complicated S. aureus CLABSI:** 4-6 weeks (if endocarditis or metastatic foci)
- **Candida CLABSI:** Remove catheter + echinocandin (first-line) → 14 days after first negative culture
- **CoNS CLABSI:** Can consider catheter retention (if tunneled/port) + antibiotic lock therapy
- **CIED infection:** COMPLETE device removal (generator + all leads) MANDATORY
- **Partial CIED removal (generator only) = treatment failure**
- **CIED antibiotic duration starts AFTER complete device removal**
- **CoNS = #1 pathogen** for both CLABSI (30-40%) and CIED infection (50-60%)
- **CIED reimplantation:** Wait 72h (CoNS), 14 days (S. aureus uncomplicated), 4-6 weeks (endocarditis)
- **Tyvalzi envelope (minocycline/rifampin):** Reduces CIED infection by 40% (FDA 2019)
- **CLABSI prevention:** Chlorhexidine skin prep, subclavian site, maximal barrier precautions

**Media:** None

**Sources:** [IDSA 2009 - Intravascular Catheter-Related Infections], [ESC 2019 - CIED Infections], [AHA 2018 - CIED Lead Management], [CDC 2024 - CLABSI Prevention Guidelines], [NEJM 2019 - Tyvalzi envelope trial], [Circulation 2023 - S. aureus bacteremia management], [PMC 2024 - CIED infection outcomes]
